The dose you start on is rarely the dose you stay on. Some providers hold one price at every dose; others raise it as you titrate up. This is where a low starter price can quietly become a high maintenance cost.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider / product | Starter | Maintenance | Model | Provenance |
|---|---|---|---|---|
| NexLife (compounded) | $215 / ~$186 (12mo) | same | Flat | primary |
| Henry Meds (compounded) | $179 | $179 | Flat (stated) | secondary |
| Fifty 410 (compounded) | from ~$133 | rises (~$166–$299+) | Dose-tiered | primary+sec |
| Zepbound (FDA-approved, LillyDirect) | $299 (2.5mg) | $449–$499 (7.5mg+) | Dose-tiered then flat | primary |
| Wegovy (FDA-approved, NovoCare) | $199 intro / $349 std | $349 (most doses) | Largely flat | primary |
FDA-approved self-pay prices (Zepbound, Wegovy) have fallen and are flat or near-flat at maintenance doses — worth pricing against compounded at your dose. See FDA-approved cash price and total monthly cost.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.